## 1 Supplementary Material:

2

# 3 Supplementary Table S1: List of Radiomic Features

<b>Feature Category</b>	Features
First Order Statistics	Energy
	Total Energy
	Entropy
	Minimum
	10th Percentile
	90th Percentile
	Maximum
	Mean
	Median
	Interquartile Range
	Range
	Mean Absolute Deviation
	Robust Mean Absolute Deviation
	Root Mean Squared
	Standard Deviation
	Skewness
	Kurtosis
	Variance
	Uniformity
3D Shape	Mesh Volume
	Voxel Volume
	Surface Area
	Surface Area to Volume Ratio
	Sphericity
	Compactness
	Spherical Disproportion
	Maximum 3D Diameter
	Maximum 2D Diameter (Axial)
	Maximum 2D Diameter (Coronal)
	Maximum 2D Diameter (Sagittal)

	Major Axis Length
	Minor Axis Length
	Least Axis Length
	Elongation
	Flatness
Gray level Co-occurrence	Autocorrelation
Matrix	Joint Average
	Cluster Prominence
	Cluster Shade
	Cluster Tendency
	Contrast
	Correlation
	Difference Average
	Difference Entropy
	Difference Variance
	Difference Average
	Joint Energy
	Joint Entropy
	Informational Correlation
	Inverse Difference Moment
	Inverse Difference Moment Normalized
	Inverse Difference
	Inverse Difference Normalized
	Inverse Variance
	Maximum Probability
	Sum Average
	Sum Entropy
	Sum of Squares
Gray Level Size Zone Matrix	Small Area Emphasis
	Large Area Emphasis
	Gray Level Non-Uniformity
	Gray Level Non-Uniformity Normalized
	Size-Zone Non-Uniformity
	Size-Zone Non-Uniformity Normalized

	Zone Percentage
	Gray Level Variance
	Zone Variance
	Zone Entropy
	Low Gray Level Zone Emphasis
	High Gray Level Zone Emphasis
	Small Area Low Gray Level Emphasis
	Small Area High Gray Level Emphasis
	Large Area Low Gray Level Emphasis
	Large Area High Gray Level Emphasis
Gray Level Run Length	Short Run Emphasis
Matrix	Long Run Emphasis
	Gray Level Non-Uniformity
	Gray Level Non-Uniformity Normalized
	Run Length Non-Uniformity
	Run Length Non-Uniformity Normalized
	Run Percentage
	Gray Level Variance
	Run Variance
	Run Entropy
	Low Gray Level Run Emphasis
	High Gray Level Run Emphasis
	Short Run Low Gray Level Emphasis
	Short Run High Gray Level Emphasis
	Long Run Low Gray Level Emphasis
	Long Run High Gray Level Emphasis
Gray Level Dependence	Small Dependence Emphasis
Matrix	Large Dependence Emphasis
	Gray Level Non-Uniformity
	Dependence Non-Uniformity
	Dependence Non-Uniformity Normalized
	Gray Level Variance
	Dependence Variance
	Dependence Entropy

	Low Gray Level Emphasis
	High Gray Level Emphasis
	Small Dependence Low Gray Level Emphasis
	Small Dependence High Gray Level Emphasis
	Large Dependence Low Gray Level Emphasis
	Large Dependence High Gray Level Emphasis
Neighboring Gray Tone	Coarseness
Difference Matrix	Contrast
	Busyness
	Complexity
	Strength

Supplementary Table S1: A list of radiomic features extracted from a liver volume. The features include 

computations related to the statistics, shape, and gray-level relationships of the image.

### 8 Supplementary Table S2: Radiomic Deviations from IBSI Standards

Computation	PyRadiomics Implementation	IBSI Guidelines
Binning	Discretizes gray values with fixed bins	Discretizes using fixed bin width
	with edges equally spaced from 0.	equally spaced from minimum of
		resegmentation range
Resampling	Aligns to the corner of the original voxel	Aligns to the center of the image
Gray value rounding	Does not implement resampling of	Resamples to similar resolution of
	similar resolution to original intensity	original CT image i.e. rounding to
	values, with the argument that differences	integer resolution of Hounsfield
	are likely to be minor and may add	Units from the original CT
	complexity.	intensity data.
Mask resampling	Resamples to nearest neighbor	Allows selection of different
		interpolators for resampling

9

- Supplementary Table S2: A list of deviations from the feature extraction guidelines by the Image
- 11 Biomarker Standardisation Initiative (IBSI).

#### Supplementary Equation S3: Random Survival Forest Algorithm

- 14 To build a survival tree that predicts survival from an input vector of radiomic features, the following
- steps are taken:

16 17

13

- 1. Select *N* samples from the dataset.
- 2. For each sample i = 1, 2, ... N, initialize a binary decision tree with max depth D.
- 3. At each node, iterate through set of features  $X = \{x_1, x_2, ... x_N\}$  and its range of feature values  $S = \{x_1, x_2, ... x_N\}$
- 20  $\{S_{min}, S_{max}\}$  to select feature  $x_i$  and a threshold split value  $s_i$  such that:

21

22

23

$$L(x_i, s_i) \ge L(x, s) \ \forall \ x \in X, s \in S$$

Where L(x,s) is the log rank test such that

24

$$L(x,c) = \frac{\sum_{i=1}^{N} E_{i,1} - Y_{i,1} \frac{E_i}{Y_i}}{\sqrt{\sum_{i=1}^{N} \left(\frac{Y_{i,1}}{Y_i}\right) \left(1 - \frac{Y_{i,1}}{Y_i}\right) \left(\frac{Y_i - E_i}{Y_i - 1}\right) E_i}}$$

- Where at time  $t_i$ ,  $E_i$  is the number of events at time  $t_i$   $E_{i,j}$  is the number of events at a daughter
- node j,  $Y_i$  is the number of patients with an events or at risk at time  $t_i$ , and  $Y_{i,j}$  is the number of
- patients with an event or at risk at a daughter node j
- 4. Continue to grow children nodes unless the children node has no more than *M* surviving samples,
- where M is a user-defined hyperparameter
- 30 5. Calculate the cumulative hazard function for the decision tree with the Nelson-Aalen estimator:

31

$$H_q(t) = \sum_{t_{p,q} \le t} \frac{E_{p,q}}{Y_{p,q}}$$

- Where p is a patient in the set of M patients in set  $P = \{p_1, p_2, \dots p_M\}$ , q is a node in the set of N
- nodes in set  $Q = \{q_1, q_2, \dots q_N\}$ ,  $E_{p,q}$  is the number of events at time  $t_{p,q}$ , and  $Y_{p,q}$  is the number of
- patients with an event or at risk at time  $t_{p,q}$ .
- 35
- 6. Repeat steps 1-5 *K* times to create *K* separately initialized trees, where *K* is a user-defined
- 36 hyperparameter.
- 38 39

37

7. Average the cumulative hazard function over all trees to compute the ensembled cumulative hazard.

## 40 Supplementary Table S4: Baseline variable distributions by lesion

Characteristics	All lesions (n=129)
Number of patients/lesions	97/129
Sex, n (%)	
Male	83 (64.3)
Female	46 (36.7)
Metastasis at time of diagnosis, n (%)	
M0	40 (30.0)
M1	89 (70.0)
Colorectal Histology, n (%)	
Colon	104 (80.6)
Rectal	20 (15.6)
Undetermined	5 (3.8)
Number of liver lesions at diagnosis, n (%)	
0	5 (3.9)
1	25 (19.4)
2	9 (7.0)
3-5	32 (24.8)
> 5	53 (41.0)
Undetermined	5 (3.9)
Other sites at diagnosis, n (%)	
None	101 (78.3)
Lung	12 (9.3)
Non-regional LN	3 (2.3)
Lung and non-regional LN	4 (3.1)
Other	7 (5.4)
Undetermined	2 (1.6)
RT to other sites, n (%)	
No	75 (58.1)
Before liver RT	28 (21.7)
After Liver RT	21 (16.3)
Before and after liver RT	2 (1.6)
Undetermined	3 (2.3)
RT fraction delivered, Median (IQR)	6 (5-15)
RT dose delivered, Median (IQR)	4500 (3000 - 6000)
Dose Painting - Yes, n (%)	55 (42.6)
Intended Dose Median (IQR)	6000 (4000 - 6750)
Mean RT length ± SD (Days)	11.6 (8.5)
PTV volume (cm3), Median (IQR)	94.4 (39.2 - 174.4)

Mean D95 ± SD (% of intended dose)	97.7 (11.0)
Reirradiation - Yes, n (%)	8 (6.2)
Surgery before RT, n (%)	91 (70.5)
Systemic before RT, n (%)	126 (97.7)
Pump before RT, n (%)	81 (62.8)
Lines of Chemo, Median (IQR)	3 (2 - 4)
RFA before RT, n (%)	45 (34.9)
RFA to RT lesions - Yes, n (%)	13 (10.1)
Y90 before RT - Yes, n (%)	10 (7.8)
Embolization before RT, n (%)	12 (9.3)
CEA at diagnosis, Median (IQR)	15.7 (3.38 - 176.9)
CEA at RT, Median (IQR)	18.7 (4.8 - 127.2)
Number of liver lesions at RT, n (%)	
1	57 (44.2)
2	43 (33.3)
3	12 (9.4)
≥ 4	16 (12.4)
Undetermined	1 (0.7)
Other sites at RT, n (%)	
None	52 (40.3)
Lung	27 (21.0)
Non-regional LN	10 (7.8)
Lung and non-regional LN	25 (19.3)
Other	15 (11.6)
Mean lesion 1 dimension 2 ± SD	35.2 (22.3)
Mean lesion 1 dimension $1 \pm SD$	26.0 (17.9)
Freedom from local progression (FFLP), n (%)	
Progression	55 (42.6)
No progression	67 (52.0)
Undetermined	7 (5.4)
Mean FFLP (months) ± SD	10.5 (0.4)
Any hepatic progression (AHP), n (%)	
Progression	99 (76.8)
No progression	25 (19.4)
Undetermined	5 (3.8)
Mean time to AHP (months) $\pm$ SD	7.3 (7.1)

Abbreviations: LN = lymph node, RT = radiotherapy, PTV = planning target volume, CEA = carcinoembryonic antigen, HAIP = hepatic arterial infusion pump, TARE = transarterial radioembolization. Supplementary Table S4: A table of baseline clinical variables recorded as part of standard of care, with averages computed from the set of variables per lesion. The clinical variables will be utilized alongside computational radiomic features from computed tomography scans as input data to a machine learning model to predict local progression. 

## 52 Supplementary Table S5: Baseline variable distributions by patient

Characteristics	All Patients (n=97)
Sex, n (%)	
Male	63 (64.9)
Female	34 (35.1)
Metastasis at time of diagnosis, n (%)	
M0	32 (33)
M1	65 (67)
Other sites at diagnosis, n (%)	
None	74 (76.3)
Lung	9 (9.3)
Non-regional LN	3 (3.1)
Lung and non-regional LN	4 (4.1)
Other	5 (5.2)
Undetermined	2 (2.0)
RT to other sites, n (%)	
No	58 (59.8)
Before liver RT	23 (23.7)
After Liver RT	13 (13.4)
Before and after liver RT	2 (2.1)
Undetermined	1 (1)
Number of liver lesions at RT, n (%)	
1	56 (57.7)
2	25 (25.8)
3	6 (6.2)
≥ 4	9 (9.3)
Undetermined	1 (1)
Other sites at RT, n (%)	
None	37 (38.1)
Lung	21 (21.7)
Non-regional LN	8 (8.3)
Lung and non-regional LN	17 (17.5)
Other	14 (14.4)
Freedom from local progression (FFLP), n (%)	
Progression	50 (51.6)
No progression	40 (41.2)
Undetermined	7 (7.2)
Mean time to local progression (months) $\pm$ SD	10.5 (8.8)

Any hepatic progression (AHP), n (%)		
	Progression	76 (78.4)
	No progression	16 (16.4)
	Undetermined	5 (5.2)
Mean time to AHP (months) $\pm$ SD		7.4 (6.9)

Abbreviations: LN = lymph node, RT = radiotherapy

Supplementary Table S5: A table of baseline clinical variables recorded as part of standard of care, with averages computed from the set of variables per patient. Lesion-specific variables were excluded.

## Supplementary Table S6: Dosages and number of fractions to liver metastases

Total Dose (Gy)	Fractions	BED <sub>10</sub> (Gy)	Patient Count
24	1	82	9
24	3	43	1
27	3	51	1
30	3	60	1
30	5	48	8
30	10	39	1
35	3	60	2
36	6	68	1
38	15	48	1
40	5	72	4
45	3	113	5
45	5	86	1
50	5	100	12
50	10	75	1
60	3	180	2
60	5	132	4
60	6	120	2
60	10	96	5
60	15	84	1
67.5	15	98	15
70	10	119	9
75	3	263	1

75	5	188	2
75	15	113	1
75	25	98	5
75	50	86	1
80	10	144	1

Supplementary Table S6: A list of doses to liver metastases, fractions, biologically effective dose (BED), and number of patients treated with the combination.

66	Supplementary Material S7: Link to survival models
67	
68 69	The survival models from the different feature sets are uploaded to an open repository at: https://github.com/ricky-hu/local_control_radiomics_survival_model
70	
71	